Reddit Posts
2 “Strong Buy” Penny Stocks With Over 400% Upside on the Horizon
Rockets that are loaded: STAB, CYRN, SATL, DRTS, SKYH, CYN, BWV, MLTX, PTPI, ALLG
$THCA - Low Float SPAC near NAV, with squeeze potential
Real Potential $ISPO 2.0 -- $DRTS Moon shot incoming!
DRTS is an early candidate to a squeeze!! Buy now get paid in a week.
$DRTS Annual Report “In Coming Days” Will include share breakdown
Mentions
Yeah, I’m never gonna feel bad about investing in companies that are trying to cure serious diseases. I’m bullish on SLS and DRTS because they seem to have some treatments that might radically change cancer treatments (SLS for a very specific type, DRTS much more broad application) and I want to support that kind of business. Obviously there are dilution schemes out there, but if the governance is good I’ll never regret investing in cures like that.
I can’t, I’m bought in to the hype. Sold IBRX right before it took a huge shit, bought back in with my profits and letting it ride. Im pretty sure SLS has a legit drug and will get approval and a buyout, at least enough to let some serious money ride on it. They also have a promising secondary product that will be a buyout target in a couple years. DRTS just has a cool concept and I hope they straight up cure cancer. AZTR is straight up hilarious and one of the most schizophrenic stocks I have ever seen. It’s completely disconnected from the market and I have about 1% of my portfolio in it for fun.
Hahaha. Put that money ASTS/DRTS/NLST and go chill in Thailand 4-eva
I feel that DRTS is the safest biotech play due to having PMDA approval and it having Q2 catalysts. If uw riskier but higher rewards. I would say CING due to pdufa at end of May but FDa required more info for its CMC but the drug is safe. Reminds me of RCKT but hopefully its not sell the news due to the ADHD market being worth billions. If uw non pharma. Im looking for an entry into PLSR and QIMC after a pullback from their recent spike. PYR looks interesting because of their recent development for their plasma torches. Im also keen on FLT and esp KRKNF for their upcoming earnings and their plans for their battery factory.
FP DRTS- doubles next month- FP NLST- Samsung buyout 10X in May- FP SLS- 10X July 80th event- FP IBRX- 5X September w FDA aproval for more conditions- FP into ASTS October right when before the annnounce the next launch and it finally breaks $130. Easy!
Some sources on the company and clinical trial results: https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1093491/alpha-tau-is-firing-on-all-cylinders-japan-approval-5-us-trials-and-now-pancreatic-data-heads-to-ddw/ https://www.stocktitan.net/news/DRTS/ https://www.quiverquant.com/news/Alpha+Tau+Medical+Ltd.+Announces+Acceptance+of+Abstract+on+Alpha+DaRT®+for+Pancreatic+Cancer+at+Digestive+Disease+Week+2026
DRTS - clinical oncology company with cutting edge treatment for solid cancers. They’ve patented their treatment Alpha DaRT for the treatments of solid cancers, and clinical trials have trended extremely promisingly. Full disclaimer: I’m heavily invested in this group, but after a crisis of conscious about my positions in AI and Military stocks, I wanted something to put money into I could feel good about. Cure cancer, profit. Win win.
IBRX and AMPX. Also loving SLS and DRTS. I like investing in exciting companies working on beating cancers (if the FDA doesn't derail them).
Benzinga: DRTS is Firing on All Cylinders: Japan Approval, 5 US Trials, And Now Pancreatic Data Heads to DDW https://www.benzinga.com/content/51572144/alpha-tau-is-firing-on-all-cylinders-japan-approval-5-us-trials-and-now-pancreatic-data-heads-to-ddw
I started buying today. Smallish amounts, but $RDDT, $NVDA, $LWLG, $DRTS $MU and a few others. I think these will do well in the near future IMHO. I agree that today seemed like Capitulation. Lots of stocks down big and VIX spiked!
Fellow hustler. We might be entering a recession, maybe a long nasty one, with more volatility and craziness from the Trump administration possible. But! If the world doesnt end and the Dems win in November we might be back to "normal" by end of year. You need to decide what your goals are and learn as much as you can. Most people recommend a full market fund like VOO and they have had 15-30% returns a year lately which is alot but might be around 5% for the next few years because of craziness haha. Maybe wait a few months and just watcht the market, watch voo, watch if wars expand and maybe leading to a depression. If so hold onto your money. I personally am focused on growth and invest mostly in a small number of stocks that I feel have the highest chance of high returns: DRTS, NLST, IBRX, SLS, ASTS. Some people do most in something safe and a smaller amount in high risk/high reward. Like 80% VOO and 20% some of these stocks, for instance.
I have the same feelings and will invest in DRTS. I also invest in CGTX with the same belief that the Alzheimers drug showing positive results in trials will help the many.
This is more great news for $DRTS after updated ratings from Citi at $9 target and H.C. Wainwright at $12 target
Citi and H.C. Wainwright came out with Buy ratings for $DRTS as well, with price targets as high as 12$. Citi explained: “The firm believes the company’s radiopharma platform is being underappreciated at current share levels. Alpha Tau’s broader-than-expected Japan approval in head and neck cancer is leading to partnership opportunities.” H.C. Wainwright said: “The approval in Japan further validates the Alpha DaRT platform and helps de-risk the clinical development in the U.S.”
DRTS seem to have make significant progress in the past month or two. To me, I feel like this company has the same potential in oncology biotech sector like Ondas has in drone sector but I may have overlooked some significant risks and who knows, maybe it could be like Rezolve where it looks better at the outside than inside when looking further lol
DRTS is also starting with pancreatic cancer trials this year with its Alpha Dart radiation technology which theoretically could be more effective than any drug based cure. Medical practice still prefers drug based cancer cures first before radiation but DRTS tech could be "silver bullet" to a lots of type of cancers in the future though, so far it has been extremly effective in head and neck cancers which it got Japan FDA approval for. The CEO of DRTS seems to be extremely bullish about the company and said in a conference that big blue-chip medical companies are looking to partner them and that they will be a lot different company this time next year. I don't know if he is just really optimistic or he knows something but it is really interesting to see where this company is heading in 1-2 years.
$DRTS They target cancer tumors with radiation placed directly into the tumor. No damage to healthy surrounding tissue. Approved in Japan for head and neck cancer! Treatment is much better than the current standard of care. Several studies underway. Long term opportunity. Several Billion annual revenue once approved in the U.S.
of course my high risk biotech stock DRTS is the only green today
Don’t know, don’t really care. There must always be a bear case in investing or there’s no opportunity to be bullish. If everyone can already see the value, then no one’s selling and the price has already risen. You have to buy what nobody wants when nobody wants it. Find an investment with a bear case you can live with. I can’t live with China threatening Taiwan - that’s your opportunity to buy TSM cheaper. Piper doesn’t like DRTS last week? That’s extending my opportunity to get in lower on DRTS. Long term the truth will come out. DRTS could absolutely need to raise again. But they have so much leverage now that I don’t believe it will be through an unfavorable straight dilution. Treating them like every other binary outcome biotech is a lazy failure to think. Japan will start to bring in some as-yet-unknown amount of revenue. Maybe the cash runway is longer than it looks on the balance sheet? Maybe the bears are correct that it’s shorter. But DRTS have publicly stated that big pharma is now at attention. They can choose and negotiate a partnership (or any number of financial options) among many suitors from a position of tremendous strength. If they were desperate to do a deal it could have been done already.
Love this take. I’ve thought about my own investment as ever so slightly reducing the available supply of shares, but very similar. Likeminded individuals on r/DRTS_Stock - a great community for those looking to learn more, ask questions, share tidbits.
Sometimes picking a stock is a case of 'be the change you want to see in the world'. I invest in DRTS, the demand I create pushes the stock up, the stock attracts more investors and DRTS has more financing to do what it needs to do. If my contribution, small though it may be, will help DRTS get their treatment available to patients just that little bit faster then that's money well spent in my opinion. Better that then giving it to some scam cancer charity that spends half of my donation on staff costs and marketing.
FWIW - Gemini To evaluate Alpha Tau Medical Ltd (DRTS), we have to bridge the gap between "bench and board." This is a classic "binary" biotech play: the science is elegant and potentially revolutionary, but the business is currently a race against the "burn." As of March 18, 2026, here is the diagnosis from both a medical and financial perspective. 1. The Medical Acumen: The "DaRT" Advantage Standard radiation (Beta particles/X-rays) is like a garden hose; it gets the job done but causes a lot of "splash" damage to healthy tissue. Alpha Tau’s Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is a surgical strike. * The Mechanism: It uses Radium-224. When the radium decays, it releases Radon-220, a gas that diffuses throughout the tumor. As it travels, it emits alpha particles. * Why Alpha? Alpha particles have high Linear Energy Transfer (LET). They travel only a few cell widths but deliver enough energy to cause double-strand DNA breaks. In layman's terms: standard radiation "bruises" cancer cells; alpha particles "shred" them beyond repair. * Clinical Success: They recently secured Japanese marketing approval for head and neck cancer—a massive regulatory win. They also have FDA Breakthrough Device designations for recurrent skin cancer (cSCC) and the "holy grail" of oncology: Glioblastoma (GBM). 2. The Business Acumen: Valuation & Runway From a spreadsheet perspective, Alpha Tau is a pre-revenue company in the "valley of death" between R&D and commercialization. | Metric | Current Status (March 2026) | |---|---| | Market Cap | Approximately $657 Million | | Cash Position | $76.9 Million (as of end of 2025) | | Net Loss (2025) | $42.6 Million (widening due to clinical expansion) | | Cash Runway | Estimated ~2 years (into early 2028) | | Analyst Consensus | Buy/Hold (Price targets range from $5.00 to $12.00) | The Bull Case: * Catalyst-Rich 2026: We are in a "milestone year." They are finishing enrollment for skin cancer trials (ReSTART) and expect initial Glioblastoma (brain cancer) data by Q4 2026. Brain cancer is a massive, underserved market. * Asset Efficiency: Their tech is "device-based" rather than "drug-based," which can sometimes lead to faster manufacturing scaling. The Bear Case: * Dilution Risk: While they have cash for two years, biotech companies almost always raise money before they run out. If the stock pumps on good news, expect a secondary offering. * Adoption Hurdles: Even with FDA approval, convincing hospitals to switch from standard-of-care radiation to "inserting radium seeds" requires a massive sales force and insurance reimbursement wins. The Verdict: Is it a "Good Buy"? Alpha Tau is currently a Speculative Buy for an aggressive portfolio, but a Hold for a conservative one. * Buy it if: You believe their Glioblastoma data (expected late 2026) will show even a marginal improvement over the current 5-year survival rate of ~7%. If they crack GBM, this $650M market cap could easily double or triple. * Avoid it if: You are sensitive to volatility. Clinical-stage biotechs can drop 50% overnight if a single trial misses its primary endpoint. Pro Tip: Keep a close eye on the ReSTART trial results for skin cancer. If the FDA accepts their first PMA module (submitted Jan 2026) without major pushback, the "regulatory risk" de-rates significantly.
DRTS is a great Reddit community, I think many have heard about it on Reddit and it is one of the best risk/reward opportunities on the market. It’s a revolutionary cancer treatment with all the upside in the world.
I have a fear with RCKT bc my friend invested in this stock last year when patient died in trials and the stock fell pretty hard after that. My friend stills hold the stock though waiting for the pump up in price. I feel that I have overextended my portfolio with biotech related stuff (DRTS, IMRX, MBOT, MDAI). Yesterday I added 100 shares to DRTS, DDD, NB, CTM, PDYN, MBOT and Kopin (Ondas and UMAC bought Kopin shares with 2.10 price last September for long-term potential, my average is 2.22 and sitting with 300+ shares, earnings coming up in a week or two) I also bought 200 shares of Canadian Uranium mining company Denison Mines which is under 4$ right now, should be a good entry price but there seems to be a dilution fear with it right now)
I'm long on this one as well. the abscopal effect, the ability to see systemic impact from local application of treatment, is the oncology version of the holy grail and DRTS has multiple indications of it against "last line" patients (those who have already failed at responding to chemo or traditional radiation.) m&a in radiatherapy places their valuation in the $4B to $5B range and theyre sitting on just over a $600M market cap so 10X is not at all out of the question.
DRTS is delivering radiation darts directly into cancer tumors using standard biopsy equipment, not drugs. Works on every type of solid tumor they’ve tried it on, while the tiny range of just millimeters spares healthy tissue. This opens treatment possibilities for complicated cancers like brain and pancreas. Bonus, its application seems to stimulate a systemic response, with non-treated tumors also shrinking, and existing drugs such as world #1 Keytruda showing much greater efficacy in combination. Company has been developing the tech methodically over 10 years. Multiple trials with endpoints in 2026. Just cleared for marketing in Japan. Factories being built. Product is safe to ship through standard couriers. Medical, physics and management arms of the company all solid. Somehow market cap still < $1B. Don’t take my word for it. DYOR. Look this one up.
Everyone mentioning SLS and IBRX should also mention DRTS. They‘ve got the biggest chance to make it on the market based on their product.
Biotech isn't the boogie man. Especially if the management track record is good, the trials are good and any positive indications from the FDA like fast track is involved. DRTS and IBRX are already approved for some treatments in USA, EURO and Japan so there is an income floor.
Request for HGRAF, DRTS & CTM
They've probably only just began, friend. Research DRTS trial results and see if they impress you also. I only began investing on January 1st, other than a small retirement plan. Reading about ASTS on their subreddit covinced me they might be a once in a lifetime chance and inspired me to begin self directed investment on January 1st! If I had learned of this company in January 1st, 2025 I would have started buying at $24 dollars! Haha, what are you gonna do. Anyway I saw SLS on a stock subreddit soon after and I read up on it and was again convinced it had a great chance of success. Just luck I would say, haha. I try to find smart, successful older people and listen to what they say, pro and con. With SLSL they have two drugs that look very promising so it's two raffle tickets for one. I for one don't care what the price is for all of these now- I wish they were $1 so i could buy more!-because eventually they have the potential to be huge.
DRTS for this month then buy AMPX when it dips to 15-16 range then buy SLS from May onward
**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** FDA Breakthrough Device Designation FDA TAP program inclusion FDA MDSAP certification FDA IDE’s for five cancers and counting FDA PHASE 3 completion in Q1 2026 FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) FDA approval for commercial factory in the US, with other factories built and more in planing 100% tumor response rate in early FDA trials Effective against all tumor types, including the most high unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… Activates immune system PMDA approval in Japan 55+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy, Japan…) Patents, IP and more…
**Upcoming catalysts for DRTS:** **PMDA approval in Japan** Announced last week, further details and progress to come **Keytruda trial for combination therapy** Updates from combination trials with Merck’s Keytruda, exploring systemic and metastatic potential **GBM FDA trial** Two months ago it was announced Alpha Tau has successfully treated the first GBM patient, historic news, with more patients and updates coming every month - including recent update about the second patient being successfully treated and both patients doing great **FDA Pancreas trial** Earlier than that it was announced that Alpha Tau has successfully treated a Pancreatic Cancer patient as well, after successfully completing a Pancreatic Cancer study with tens of patients in Canada. Progress and updates from the Pancreas trial could be shared along the way **Phase 3 recruitment completion for cSCC** Q1 2026, the early results are amazing **cSCC FDA approval submission** Already started submitting the data **New FDA trials launching** Most recently prostate, while next could be head & neck **Commercial manufacturing facility completion** Already approved by the FDA **Presenting at more conferences** Including Sidoti Conference in a couple of weeks, RTH & Co Radiopharma Landscape conference and others **Other stock related events** Potential strategic partnerships or licensing deals, enabled by regulatory and manufacturing readiness. Investor re ratings, like H.C. Wainwright raising price target to 12$, transitioning from pre revenue clinical stage to commercial oncology company is a major re-rating moment. Future label expansions leveraging existing approvals and platform scalability.
I usually try to scan forums for ideas and ultimatelly I decide after looking into those companies but your recommendations tend to be real solid and it's kind of hard to find better ones even though hopefully DRTS and PDYN could be in the same ballpark in terms of potential as Ondas when they properly execute their plans.
I decided to play it more safe and keep my current position in LifeMD even if current gains fade away in next few months bc biotech like RCKT is riskier even though I have huge conviction in DRTS and IMRX - those are the 2 that I feel confident in "rolling the dice" (long cash runway, insiders buying and good recent results despite share price drop in IMRX and proven tech + long cash runway in DRTS) and I can sleep well at night with those pics lol The thing is I really don't have that good financials to take more risks in investing so I try to find balance between taking risks that I can afford and try to make good enough gains (whatever that may be) at the same time.
#TLDR --- Ticker: DRTS Direction: Up Prognosis: Buy Shares (OP is packing 15,000 of them) Catalysts: Phase 3 Data (Q1 2026) & FDA Submission Treatment Plan: Zap the tumors, pump the portfolio with radioactive alpha tendies
#TLDR --- **Ticker:** DRTS (Alpha Tau Medical) **Direction:** Up 🚀 **Prognosis:** Buy shares and hold for upcoming Phase 3 data (OP is deep with 15,000 shares). **Catalysts:** Phase 3 trial results for cSCC, Pancreatic, and GBM cancers all potentially reporting this year, plus US FDA approval decisions. **Cancer's Prognosis:** Getting nuked from the inside out with alpha particles. **Biotech Risk Level:** Binary FDA gamble, but with $76M in cash and zero debt, they can at least afford their own copay if things go south.
#TLDR --- **Ticker:** $DRTS (Alpha Tau Medical) **Direction:** Up 🚀 **Prognosis:** Buy shares, hold for 2026 Phase 3 results, and pray to the FDA gods. **Catalysts:** Phase 3 trial completions starting Q1 2026 (cSCC, Pancreatic, GBM) and Japanese market expansion. **OP's Position:** 15,000 shares deep (A proper $100k+ Biotech YOLO). **Vibe:** Cure cancer, save lives, and make millions... as long as the FDA doesn't nuke it first.
Agree, the only thing stopping DRTS from reaching 100+ if the trials succeed is being bought out (great result for investors although I’d love to see it play out myself)
DRTS, very deep DD. https://www.reddit.com/r/stocks/s/qLQyXxwJ8M
The CFO is very talented, worked in investment banking for years and then chose Alpha Tau (DRTS) out of the many offers he had because he believed it was a unique opportunity and he’s helping make it a reality.
That’s the sad yet beautiful truth about the cancer market, all companies could succeed and we need them to. And DRTS could actually work alongside the others, maybe we see a combined trial sometime in the future.
My bags are not for sale, I’m long DRTS. Sharing for others to do their own research on a stock I’m really passionate about.
DRTS is a method/device (a tiny dart injected into the tumor in a reverse of the way you would take a biopsy, it contains a very low dose of radiation that has a dispersal of radiation to a very small area to impact the tumor while sparing healthy tissue, the dart/darts are later removed), IBRX is immunotherapy. There is room for DRTS and IBRX and SLS, the more treatment options (solo or in combination) to allow effective treatment, the better.
Praying DRTS could make a real difference for all patients and their families!
What’s SONA? DRTS actually had 100% response rate in early FDA trials.
**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** FDA Breakthrough Device Designation FDA TAP program inclusion FDA MDSAP certification FDA IDE’s for five cancers and counting FDA PHASE 3 completion in Q1 2026 FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) FDA approval for commercial factory in the US, with other factories built and more in planing 100% tumor response rate in early FDA trials Effective against all tumor types, including the most high unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… Activates immune system PMDA approval in Japan 55+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy, Japan…) Patents, IP and more…
**Upcoming catalysts for DRTS:** **PMDA approval in Japan** Announced last week, further details and progress to come **Keytruda trial for combination therapy** Updates from combination trials with Merck’s Keytruda, exploring systemic and metastatic potential **GBM FDA trial** Two months ago it was announced Alpha Tau has successfully treated the first GBM patient, historic news, with more patients and updates coming every month - including recent update about the second patient being successfully treated and both patients doing great **FDA Pancreas trial** Earlier than that it was announced that Alpha Tau has successfully treated a Pancreatic Cancer patient as well, after successfully completing a Pancreatic Cancer study with tens of patients in Canada. Progress and updates from the Pancreas trial could be shared along the way **Phase 3 recruitment completion for cSCC** Q1 2026, the early results are amazing **cSCC FDA approval submission** Already started submitting the data **New FDA trials launching** Most recently prostate, while next could be head & neck **Commercial manufacturing facility completion** Already approved by the FDA **Presenting at more conferences** Including Sidoti Conference in a couple of weeks, RTH & Co Radiopharma Landscape conference and others **Other stock related events** Potential strategic partnerships or licensing deals, enabled by regulatory and manufacturing readiness. Investor re ratings, like H.C. Wainwright raising price target to 12$, transitioning from pre revenue clinical stage to commercial oncology company is a major re-rating moment. Future label expansions leveraging existing approvals and platform scalability.
#TLDR --- **Ticker:** DRTS **Direction:** Up **Prognosis:** Buy Shares (OP is deep with 30,000 shares) **Upcoming Catalysts:** FDA Phase 3 results for cSCC this month, plus Pancreatic and GBM trial results later this year. **Hopium Level:** Literally curing cancer and printing tendies at the same time.
Would really recommend looking more into DRTS. Let me know if you got any specific questions or want some resources
Still can’t believe DRTS doesn’t show up in the comments of these kind of posts
There’s is so much DD you can read on how this is basically guaranteed to work that I’m not even going to get into it. Yes, it’s a biotech. Yes there are many that fail but out of those many there are always those handful of diamonds in the rough. SLS AS WELL AS IBXR are those diamonds. I can’t speak for other victor stocks as I’ve only been monitoring these two. Though I hear DRTS is also looking at a bright future.
They probably won’t get all the cases, but it’s worth noting the DRTS treatment could be combined with all other treatments, it’s safe and has even proven to have a positive effect on the immune system boosting the success of everything else. Every patient should be asking for it first or at least in addition to whatever else he or she is offered.
DRTS isn’t go to get all the cases obviously, but even if they can get 2-3% of the cases, the sale would be very high giving the company value of many billions
Keytruda, which is loosing its exclusivity, holds on to its spot as the #1 selling drug in the world. Merck would be smart to look into some kind of partnership with DRTS to keep the revenue flowing https://www.biospace.com/business/keytruda-hangs-on-to-best-seller-crown-as-glp-1s-gain-ground
I put half in $DRTS to change the way cancer is treated. The rest is diversified into: BWET GDMN FMTM FLKR This gives you oil shipping futures, gold, momentum and South Korea. I’ll put this single stock and four ETFs up against any other portfolio over the next twelve months. NFA. DYOR.
IBRX, SLS, DRTS, NLST, KORU until today
$DRTS Has been approved in Japan for Head and Neck Cancer. They have perfected the use of Radiation to treat Solid Cancers right in the tumor while not harming nearby healthy tissue. The TAM is enormous.
Parliamo un po' di DRTS
I noticed people talking strongly about CING. But how come unlike RCKT, SLS, DRTS, IBRX, there's no real posts or subreddits in the last week or month? Is it just because PDUFA is still months ahead?
I'm relatively unfamiliar with pharma. How much of an actual advantage is spinning out a separate division for Merck? Why has DRTS had negative incomes for the last five years?
VKTX coming out with a better Zepbound (Ozempic sucks) and DRTS killing cancer with alpha radiation approved in Japan today. You guys haven’t even seen the best way to lose $ in the market until you get in biotechs
For sure, me personally I’m against an acquisition, and I think Uzi the CEO is of the same mindset and won’t sell until DRTS reaches its full potential
Great Q, there currently isn’t any publicly known deal, what I’m saying is Merck should be looking into such a deal and is already holding a combined trial with DRTS. Actually DRTS might be the one to turn such a deal down, since they work with all treatments and might not want to tie themselves to any specific one.
For sure, although it’s worth noting that this is only one of the DRTS trials, they have hundreds of successfully treated patients, and are now testing for systemic and metastatic patients with Keytruda.
Wow! The Keytruda + DRTS results sound incredible. Where can I find more info on this?
Really solid take. The market clearly understands that this move isn’t defensive it’s proactive. Spinning out a dedicated cancer division right as the patent clock is ticking shows Merck isn’t waiting around for the cliff to hit. The DRTS combo angle is especially interesting. Even if we haircut the early data because of sample size, moving response rates that dramatically is not something you ignore. If that signal holds in larger trials, it’s a legit franchise extending strategy, not just incremental upside. You’re right to flag the risks execution and scalability matter but this feels more like repositioning for the next growth cycle than scrambling to plug a hole. Definitely one to watch closely.
People don't realize that DRTS didn't just receive PMDA approval - they got a seven year exclusive on the market. With Merck forming a separate cancer division, one of two things will happen: 1. Merck and DRTS partner to extend Keytruda viability/efficacy. $MRK has massive distribution for their $30B baby. 2. Merck takes out DRTS in M&A. Given the latest radiotherapy M&A, I expect we would see a $4B floor and a $5-$6B deal. (N.F.A./D.Y.O.R.)
**Sources** Merck announcement: https://finance.yahoo.com/news/merck-create-separate-cancer-business-112250919.html DRTS approved in Japan: https://finance.yahoo.com/news/alpha-tau-medical-receives-japanese-140000178.html
DRTS and IBRX doing particularly well and looks like SLS is on an upswing.
Ok ride IBXR up then put gains into DRTS ride that up put gains into NLST ride that up put gains into SLS ride that up put gains into ASTS get a pina colada.
$DRTS see first overseas approval in Japan for it's DaRT therapy to treat unresectable locally advanced or recurrent head and neck cancer. FDA and EMA approvals next
DRTS just posted about it [https://www.reddit.com/r/smallstreetbets/comments/1rcqx89/a\_chart\_always\_shows\_what\_the\_insiders\_know\_let/?utm\_source=share&utm\_medium=web3x&utm\_name=web3xcss&utm\_term=1&utm\_content=share\_button](https://www.reddit.com/r/smallstreetbets/comments/1rcqx89/a_chart_always_shows_what_the_insiders_know_let/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button)
**DRTS’s clinical, regulatory, financial and commercial achievements and progress:** FDA Breakthrough Device Designation FDA TAP program inclusion FDA MDSAP certification FDA IDE’s for five cancers and counting FDA PHASE 3 completion in H1 2026 FDA Phase 2 and other stages of trials going on in parallel for different indications (cancer types) FDA approval for commercial factory in the US, with other factories built and more in planing 100% tumor response rate in early FDA trials Effective against all tumor types, including the most high unmet needs like Pancreas, Lungs, Brain (GBM), Breast etc… Activates immune system 55+ clinical sites worldwide (including USA, UK, Canada, France, Germany, Russia, Italy, Japan…) Patents, IP and more…
**Upcoming catalysts for DRTS:** **PMDA approval in Japan** Expected to be announced any day **Keytruda trial for combination therapy** Updates from combination trials with Merck’s Keytruda, exploring systemic and metastatic potential **GBM FDA trial** Two months ago it was announced Alpha Tau has successfully treated the first GBM patient, historic news, with more patients and updates coming every month - including this months update about the second patient being successfully treated and both patients doing great **FDA Pancreas trial** Earlier than that it was announced that Alpha Tau has successfully treated a Pancreatic Cancer patient as well, after successfully completing a Pancreatic Cancer study with tens of patients in Canada. Progress and updates from the Pancreas trial could be shared along the way **Phase 3 recruitment completion for cSCC** Q1 2026, the early results are amazing **cSCC FDA approval submission** Already started submitting the data **New FDA trials launching** Most recently prostate, while next could be head & neck **Commercial manufacturing facility completion** Already approved by the FDA **Presenting at more conferences** Including Citi’s 2026 Oncology Leadership Summit this month and others **Other stock related events** Potential strategic partnerships or licensing deals, enabled by regulatory and manufacturing readiness. Investor re ratings, transitioning from pre revenue clinical stage to commercial oncology company is a major re-rating moment. Future label expansions leveraging existing approvals and platform scalability.
Start with the basics. The market cap for DRTS is currently at $600M. This, combined with horrible PR, has ensured that the volume in the stock and the market cap until recently, has kept institutional investors away. This was, until January, a pure retail play. Any one of the solid tumor targets that Alpha Tau is targeting is a multi-Billion dollar market. Who’s the current leader in GBM cancer? There isn’t one. Who’s the leader in PanC? Sadly, it’s a cocktail of horrible chemo poisons or, if you’re lucky, they’ll surgically do a replumbing of your innards. Alpha Tau has already shown incredible results in PanC and every month there is another FDA approved win in GBM. Gotta love clockwork catalysts if you’re a biotech investor. The company sits in the radiapharm space where M&A has been steroid level active. Previous deals with inferior treatments have gone in the $4B range (hearken back to their current market cap and simple math makes your wallet itch.) Keytruda is Merck’s $30B baby. It’s the biggest money making drug on planet earth. It has a whopping 30% success rate. Recent studies of Alpha Tau in conjunction with Keytruda push that efficacy rate north of 90%. What’s that worth to a thirty billion United States dollars drug? All of that is why I’m long. Here’s why I’m planning my retirement off of $DRTS. Something miraculous is happening because of the way their brachytherapy works. The local application of the alpha radiation isn’t just destroying the double helix of the tumors dna strand; somehow the immunity system is being retrained systemically from the local application of the radiation. If you’ve ever dreamed of being insanely wealthy, reread that last sentence a few times. I don’t believe they set out to radically upgrade the compromised immunity system via the local application of radiation but those are the results they’ve shown and reported at the JP Morgan conference a few weeks ago. As of today, all of DRTS tests are against people who are wiped out. No hope. Inoperable. Failed chemo. Shattered and burned by radiation. And they’re having amazing results. What do you think could happen if what is essentially an outpatient process (saving misery for the patient and money for the insurers) that anyone who’s ever done a biopsy (Alpha Tau made it nearly identical to a biopsy to ensure easy training) could perform hit not at the last line of attack but the first? What if patients were seeing the same efficacy results before their bodies (and souls) were depleted? Would any oncologist in the world pump their patient full of chemo and send them home with a poison filled fanny pack if they could just destroy the solid tumor in the office? You know the answer. It’s a great day to be a $DRTS investor and it’s looking like very dark days indeed if you’re a solid cancer tumor. Obviously, this is not financial advice and you should do your own research. But yes, I’m long on DRTS because: 1. Fuck cancer and 2. I like making millions while saving millions of lives.
IBRX blows up I roll into DRTS>DRTS blows up I roll into SLS> SLS blows up I roll into ASTS= I'll have $1,000 😎
bought the PATH dip and rolled DRTS calls
Today DRTS is holding a sideways trend. Two catalysts are expected to emerge in the first quarter of 2026 and will suddenly be confirmed. Given that investor anticipation for the expected event is high, the impact on the stock will be equally strong once positive responses arrive! Patience is the winning weapon.
DRTS will have positivity on all PMDA catalysts and will also prepare a platform for trading of alpha radio technology produced in hempair for trading all over the world will suddenly explode
Ah cool! I'm heavy in SLS and DRTS. Just dive right in small bios while I'm new to investing 😁
Waiting for DRTS, NLST, SLS to do anything first so I can ride the wave 👋
Recommendation to look into DRTS. A revolutionary cancer treatment that is at the turning point from clinical-stage pre-revenue company to commercial platform. The patented tech delivers alpha radiation into the tumors, killing the cancer cells while sparing healthy tissue (and even awakens the immune system and teaches it to fight cancer elsewhere in the body). It’s effective against all solid tumors, even the most high unmet needs like Pancreas and GBM (both have active in-human FDA trials with amazing results). DRTS has 55+ clinical sites worldwide, FDA Breakthrough Device Designation, fully funded with an experienced management team. NFA and DYOR but worth your time!
Learn all you can. Use a play money account to practice without losing anything for a few months. RKLB is a good company and stocks go up amd down. If you're investing you want it to go up over months or years. If your swing trading you want it to go up for a few days or weeks and sell. Thats jard to do and if you're only doing it with 100$ you're only gonna make $20 sometime. Focus on becoming valuable yourself so you can make more money and have more to save and invest. Many people will tell you too Voo and chill and that will be profitable in the future. If you want higher returns split up your investment money and pick 4 or 5 stocks and etfs that are in different fields and buy them. But stop losses on them. I do 15% below the price I paid. I like stocks that are already doing well and when they go up a good amount I change the stop loss to 15% under the new price. Here are some of my faves right now: IEZ, UWY, FIX, SII, DRTS. Good luck bro! STOP LOSS!
ASTS, RKLB, NBIS, DRTS, PL, RCAT take your pick or maybe the TSMCs will still be the next tsmc you never know
Uuuuuuuu! Also NLST buyout and DRTS approvals.
Schwab tells me i need to place an initial order through a broker for DRTS.
we want all forms of advancement to defeat cancer to succeed that is without question. those of you who are excited about this please check out the company DRTS. their alpha particle delivery device is defeating cancer tumors in all sorts of cancers and is still awaiting fda approval. it is about to receive approval in japan and the company is poised to manufacture their own products to bring to market. also check out IBRX and SLS. fuck cancer